Display options
Cite
Irwin I. The Neurotoxin l-Methyl-4-Phenyl-l,2,3,6-Tetrahydropyridine (MPTP): A Key to Parkinson's Disease?. Pharm Res. 1986;3(1):7-11doi: 10.1023/A:1016312629652.
Irwin, I. (1986). The Neurotoxin l-Methyl-4-Phenyl-l,2,3,6-Tetrahydropyridine (MPTP): A Key to Parkinson's Disease?. Pharmaceutical research, 3(1), 7-11. https://doi.org/10.1023/A:1016312629652
Irwin, I. "The Neurotoxin l-Methyl-4-Phenyl-l,2,3,6-Tetrahydropyridine (MPTP): A Key to Parkinson's Disease?." Pharmaceutical research vol. 3,1 (1986): 7-11. doi: https://doi.org/10.1023/A:1016312629652
Irwin I. The Neurotoxin l-Methyl-4-Phenyl-l,2,3,6-Tetrahydropyridine (MPTP): A Key to Parkinson's Disease?. Pharm Res. 1986 Feb;3(1):7-11. doi: 10.1023/A:1016312629652. PMID: 24271351.
Copy Download .nbib Format: NLM
Share it on

Pharm Res. 1986 Feb;3(1):7-11. doi: 10.1023/A:1016312629652.

The Neurotoxin l-Methyl-4-Phenyl-l,2,3,6-Tetrahydropyridine (MPTP): A Key to Parkinson's Disease?.

Pharmaceutical research

I Irwin

Affiliations

  1. Institute for Medical Research, 2260 Clove Drive, San Jose, California, 95128.

PMID: 24271351 DOI: 10.1023/A:1016312629652

Abstract

Since the recognition that the compound l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) is a potent inducer of chronic and irreversible parkinsonism in humans, it has been the object of intense and extensive research activity. The fact that MPTP selectively kills cells in the pars compacta of the substantia nigra and produces a syndrome in human and nonhuman primates that is virtually indistinguishable from the idiopathic disease has led to hope that understanding the mechanism of action of this toxin may shed light on the underlying biochemical pathology that is responsible for cell death in Parkinson's disease. A brief overview of Parkinson's disease is presented, and current data regarding the effects, biotransformation, and mechanism of action of MPTP are discussed.

References

  1. Neurosci Lett. 1985 Sep 6;59(3):259-64 - PubMed
  2. Nature. 1984 Oct 4-10;311(5985):464-7 - PubMed
  3. Life Sci. 1985 Jan 21;36(3):225-30 - PubMed
  4. Science. 1984 Aug 3;225(4661):529-31 - PubMed
  5. Mod Probl Pharmacopsychiatry. 1983;19:170-6 - PubMed
  6. Life Sci. 1985 Jan 21;36(3):207-12 - PubMed
  7. Proc Natl Acad Sci U S A. 1985 Apr;82(7):2173-7 - PubMed
  8. Eur J Pharmacol. 1984 Apr 20;100(2):189-94 - PubMed
  9. Lancet. 1983 Dec 24-31;2(8365-66):1457-9 - PubMed
  10. Biochem Biophys Res Commun. 1984 Dec 14;125(2):831-5 - PubMed
  11. Science. 1985 Oct 11;230(4722):181-3 - PubMed
  12. Science. 1984 Sep 28;225(4669):1460-2 - PubMed
  13. Science. 1984 Jun 8;224(4653):1083-5 - PubMed
  14. Science. 1984 Sep 28;225(4669):1480-2 - PubMed
  15. J Neurochem. 1985 Jan;44(1):117-27 - PubMed
  16. Life Sci. 1985 Jan 21;36(3):237-42 - PubMed
  17. Science. 1984 Jun 29;224(4656):1451-3 - PubMed
  18. Life Sci. 1985 Jan 21;36(3):201-6 - PubMed
  19. Drug Metab Dispos. 1985 May-Jun;13(3):342-7 - PubMed
  20. Biochem Biophys Res Commun. 1984 Apr 30;120(2):574-8 - PubMed
  21. Acta Neurol Scand Suppl. 1983;95:103-5 - PubMed
  22. Proc Natl Acad Sci U S A. 1983 Jul;80(14):4546-50 - PubMed
  23. Biochem Biophys Res Commun. 1985 Mar 15;127(2):707-12 - PubMed
  24. Mol Pharmacol. 1978 Jul;14(4):644-53 - PubMed
  25. Science. 1983 Jul 1;221(4605):65-7 - PubMed
  26. Neurosci Lett. 1984 Jul 13;48(1):87-92 - PubMed
  27. Nature. 1984 Oct 4-10;311(5985):467-9 - PubMed
  28. Science. 1983 Feb 25;219(4587):979-80 - PubMed
  29. Brain Res. 1984 Feb 6;292(2):390-4 - PubMed
  30. Psychiatry Res. 1979 Dec;1(3):249-54 - PubMed
  31. J Org Chem. 1947 Nov;12(6):894-903 - PubMed
  32. J Neural Transm Suppl. 1983;19:89-103 - PubMed
  33. Eur J Pharmacol. 1984 Oct 30;106(1):209-10 - PubMed

Publication Types